Boehringer Ingelheim announces appointments Board of Managing Directors

Boehringer Ingelheim announces today that the Shareholders’ Committee has made the following changes to the Board of Managing Directors:

Carinne Brouillon, member of the Board of Managing Directors with responsibility for the Human Pharma Business Unit, has informed the Shareholders of her intention to retire from the company per October 1, 2024.

Shashank Deshpande, member of the Board of Managing Directors with responsibility for the Animal Health Business Unit, has been appointed to lead the Human Pharma Business Unit, effective October 1, 2024. Shashank Deshpande joined the Board of Managing Directors on September 1, 2023.

Dr. Armin Wiesler, Regional Managing Director and Head of Animal Health for Southeast Asia, Korea, Australia and New Zealand has been appointed a member of the Board of Managing Directors, effective October 1, 2024. He will succeed Shashank Deshpande to lead the Animal Health Business Unit from this date.

Christian Boehringer, Chairman of the Shareholders’ Committee commented: “I would like to thank Carinne for her leadership and for transforming our Human Pharma business to prepare the organization to launch our rich pipeline in the coming years. Her collegiality, positivity and patient-first mindset were felt throughout our organization.”

Hubertus von Baumbach, Chairman of the Board of Managing Directors added: “I want to thank Shashank for accepting his new role. His Board experience, longstanding leadership in our two largest human pharma markets and his pharma marketing background make him an excellent successor to Carinne, who I wish all the best for the future. I also welcome Armin to our Board. His animal health industry knowledge and deep commercial understanding make him well prepared to continue the transformational work Shashank successfully started in Animal Health.”

Shashank Deshpande joined Boehringer Ingelheim in 2012. Prior to his current Board mandate, he was Country Managing Director in Japan. Earlier, he held human pharma leadership and marketing positions in Japan and Germany. Shashank Deshpande is a highly experienced leader, with a strong business background, who lived and worked across Asia, Europe and North America. He holds a Master’s degree in Business Administration from the University of Hamburg, Germany.

Armin Wiesler joined Boehringer Ingelheim in 2008. Prior to his regional leadership role since 2021, he performed local, regional and global roles in corporate strategy and development, human pharma marketing and animal health. Armin Wiesler was a General Manager in Thailand, worked at Boehringer’s US headquarters and spent six years in corporate roles in Ingelheim. Dr. Wiesler holds a Doctorate and a Master’s degree in Economics from the University of Freiburg, Germany.

Boehringer Ingelheim
 

Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. More than 53,000 employees serve over 130 markets in the two business units Human Pharma and Animal Health. Learn more at www.boehringer-ingelheim.com